Products & Pipeline
Partnering Opportunities
Gastrointestinal ReProgramming
(GaRP) complementary medicine
Anatara is seeking to partner with international pharmaceutical and consumer health companies for the commercialisation of its Gastrointestinal ReProgramming (GaRP) dietary supplement product which has been designed to address the primary underlying factors associated with human gastrointestinal conditions such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), where there is a significant unmet need and market opportunity.
In February 2019, Anatara announced breakthrough positive efficacy data from its in vitro Proof of Concept studies of its GaRP dietary supplement product in both reducing inflammation and restoring gut integrity.
Further Information
With preclinical development successfully completed, recruitment for a clinical trial in human subjects with IBS commenced in August 2021.
The trial indicated that the GaRP product may offer relief from a number of IBS-related symptoms.
Further information can be found here.
Want to stay up to date with our trials and latest news?
Sign up here